Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
Sunshine Biopharma (SBFM) has filed a patent application for a novel treatment targeting neurodegenerative disorders. This application, dated October 1, 2021, presents data indicating that specific mRNA molecules can protect neuronal cells from oxidative stress, a condition mimicking neuronal degeneration. Neurodegenerative diseases affect millions globally, with no known cures. The company aims to develop a therapeutic approach that could potentially alleviate symptoms and halt disease progression.
- Filed a patent application for a potential treatment for neurodegenerative disorders.
- Experimental results indicate mRNA molecules provide protective effects against oxidative stress in neuronal cells.
- None.
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a patent application for a potential new treatment for neurodegenerative disorders. Sunshine Biopharma’s patent application contains experimental results showing that certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics neuronal degeneration. This new patent application has a priority date of October 1, 2021.
Neurodegeneration refers to the progressive loss of neuronal function, which may ultimately result in cell death. Neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis, Alzheimer's disease, and Huntington's disease. Neurodegeneration can occur in the brain as well as in the peripheral nervous system. At present, there is no known way to reverse the progressive degeneration of neurons and as such these diseases are considered to be incurable.
Recent biochemical studies have revealed many underlying similarities among these diseases at the sub-cellular level. These similarities suggest that a given therapeutic approach for one neurodegenerative disease might ameliorate other diseases in the class.
Neurodegenerative diseases affect millions of people worldwide. Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases. According to the CDC, as many as 5.8 million Americans were living with Alzheimer's disease in 2020. An estimated 1.2 million people in the United States could be living with Parkinson’s disease by 2030. There is currently no way to slow down the progression of these and other neurodegenerative diseases.
“We are heartened by this recent finding in our ongoing mRNA-as-therapeutic-agents research that certain mRNA molecules provide differentiated neuronal cells full protection against hydrogen peroxide induced oxidative stress, a system commonly used to study neurodegeneration in vitro,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are excited about this discovery for patients suffering from neurodegenerative disorders. Our possible mRNA treatment could arrest progression of neurodegeneration, alleviate symptoms, relieve pain, and increase mobility,” he added.
About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 4.5 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest
replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting.
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
FAQ
What recent patent application did Sunshine Biopharma file?
How could Sunshine Biopharma's new treatment impact neurodegenerative diseases?
What is the focus of Sunshine Biopharma's research?
Is there a known cure for neurodegenerative diseases?
